Discover NfL: The future of MS testingUnlocking new insights with the world’s first CE-marked1 blood test for relapsing multiple sclerosis (RMS).

A New Era in MS management begins here.

Neurofilament Light Chain (NfL) is redefining how relapsing multiple sclerosis (RMS) is managed. As the first CE-marked¹ blood-based biomarker for RMS, NfL provides fast, reliable, and clinically actionable insights - delivered through a simple blood draw.

NfL is more than just a test. It’s a breakthrough in precision neurology, helping to prognosticate the risk of future disease activity, allowing quick and informed treatment decisions - all with minimal burden on patients.

What is MS and RMS?

Multiple Sclerosis, (MS), is an unpredictable disease of the central nervous system. The nervous system controls many critical functions – from walking to problem-solving. Relapsing MS (RMS) refers to the forms of MS characterized by flare-ups or attacks of the disease that last for at least 24 hours.

Siemens Healthineers NfL Assay MS

MS is a disease of the central nervous system

MS is an inflammatory immune-mediated disease of the CNS that results in myelin destruction and axonal damage.

Siemens Healthineers NfL Neuron

MS occurs when immune cells attack nerve cells (neurons)

Disrupted CNS nerve signals produce the signs and symptoms of MS.

Siemens Healthineers NfL Brain

Variability can challenge effective patient management

Effective management of RMS is associated with reduced disease activity and progression.

Someone is diagnosed with MS every 5 minutes and cases have grown 30% since 2013

Multiple sclerosis is highly variable in its presentation and progression with management that traditionally involves multiple complex and time-consuming tests, causing care providers to wait for important results while potentially putting physical and emotional strain on an already vulnerable patient population.

As an easy-to-use, reproducible and automated test with a clear clinical decision threshold, NfL allows labs to make significant contributions in the optimization of care for patients with RMS—increasing clinical confidence and strengthening collaboration with key clinical partners. The medical community’s understanding of MS is evolving rapidly. Staying informed on the latest discoveries and MS innovations is the surest way to support clinical partners and the 2.9 million patients living with the condition.

million people living with multiple sclerosis globally
Siemens Healthineers MS Prevalence Map

A simple test with global potential

2.9 million people worldwide are affected by MS, with an estimated 85% having relapsing MS.2,3 NfL testing can make optimized care far more accessible to more patients with RMS. Discover how NfL can help elevate MS care by reading available, peer-reviewed information on NfL as a biomarker for this disease.

Healthy Neuron
Axonal damage

A closer look: use the slider to see how NfL is released

How NfL is released from nerve cells

MS results in myelin destruction and axonal damage. This axonal injury and degeneration of neurons results in the release of NfL into cerebrospinal fluid, or CSF, and blood. NfL levels can indicate risk of disease activity and progression.

Review the research

“NfL addresses a major unmet need in management of MS for blood biomarkers...”
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management
Freedman, Mark S. et al.eBioMedicine, Volume 101, 104970

More Information

Siemens Healthineers NfL Assay on the CI Analyzer

NfL Product Page

Unlock powerful insights into relapsing multiple sclerosis (RMS) with a simple, accessible blood test.

Siemens Healthineers NfL Assay on Atellica Solution

Discover the Atellica Solution

Seamlessly bring NfL testing into your lab with the Atellica Solution portfolio, which delivers the scalability, precision, and efficiency your lab needs to deliver fast, reliable results in relapsing multiple sclerosis (RMS) care.

1
CE 0197. NfL is not available for sale in the United States and may not be commercially available in all countries. Future availability cannot be guaranteed and is dependent on local regulatory requirements.

The Atellica IM NfL assay, in conjunction with clinical, imaging, and laboratory findings, is intended to be used as an aid in identifying adult patients between 18–55 years of age with Relapsing Multiple Sclerosis (RMS), who are at a higher versus lower risk of MS disease activity, as defined by new or enlarging T2 (neT2) magnetic resonance imaging (MRI) lesions, within a 2 year period.
2
Number of people with MS: Atlas of MS Number of people with MS | Atlas of MS. https://www.atlasofms.org/map/global/epidemiology/number-of-people-with-ms
3
Empowering people affected by MS to live their best lives. National Multiple Sclerosis Society. https://www.nationalmssociety.org/understanding-ms/what-is-ms/types-of-ms/relapse-remitting-ms